Validation and threshold identification of a prescription drug monitoring program clinical opioid risk metric with the WHO alcohol, smoking, and substance involvement screening test
| Autor: | Theresa Winhusen, Stacey Frede, Margie E. Snyder, M. Aryana Bryan, Omolola A. Adeoye-Olatunde, Jennifer L. Brown, Gerald Cochran, Brooke Taylor, Ziji Yu, Andrew Ferguson, Udi E. Ghitza, Elizabeth Charron, Nadia Bayyari |
|---|---|
| Rok vydání: | 2021 |
| Předmět: |
Adult
medicine.medical_specialty Narcotic medicine.medical_treatment Concurrent validity Pharmacy Toxicology World Health Organization Article Medicine Humans Pharmacology (medical) Medical prescription Pharmacology Receiver operating characteristic business.industry Risk metric Smoking Opioid-Related Disorders Analgesics Opioid Psychiatry and Mental health Cross-Sectional Studies Emergency medicine Prescription Drug Monitoring Programs Metric (unit) business Kappa |
| Zdroj: | Drug Alcohol Depend |
| ISSN: | 1879-0046 |
| Popis: | BACKGROUND: Prescription drug monitoring programs (PDMPs) are critical for pharmacists to identify risky opioid medication use. We performed an independent evaluation of the PDMP-based Narcotic Score (NS) metric. METHODS: This study was a one-time, cross-sectional health assessment within 19 pharmacies from a national chain among adults picking-up opioid medications. The NS metric is a 3-digit composite indicator. The WHO Alcohol, Smoking, and Substance Involvement Screening Test (ASSIST) was the gold-standard to which the NS metric was compared. Machine learning determined optimal risk thresholds; Receiver Operating Characteristic curves and Spearman (P) and Kappa (K) coefficients analyzed concurrent validity. Regression analyses evaluated participant characteristics associated with misclassification. RESULTS: The NS metric showed fair concurrent validity (area under the curve≥0.70; K=0.35; P=0.37, p |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|
Full Text from ScienceDirect